If you want to skip directly to the donate link, go here. But really! You should read the whole thing.
As part of fundraising using bitcoin, I promised that if I raised more than 10 BTC (I got a bit more than 11 BTC total), I’d start testing other molecules in the 9DS family, one of which would be named “Satoshimycin”. Why do we want more compounds? Drug discovery is a bit of a gamble. Sometimes, drug candidates can fail in the late stage due to something you couldn’t have predicted from first principles. It would be silly to discount the 9DS family of compounds and, broadly speaking, the medicinal strategy, based on the success or failure of a single example. Given that drug discovery is an expensive process, one of the most effective ways for indysci to promote open-source pharmaceuticals is to shepherd multiple candidates through early stages, especially since within the 9DS family, the infrastructure and strategies are shared.
Luckily, this is a relatively easy process; the way 9DS is made is by feeding a molecule to the soil bacteria that produce sibiromycin. The bacteria integrate this compound by substituting it in the sibiromycin structure, effectively deleting the section that causes cardiotoxicity. If we feed a slightly modified compound instead, the homologous modification should be incorporated into 9DS.